Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 13/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276251 | 1.00 | TP53 (0.59) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL276560 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL277153 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL8354220 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL11876775 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL5882600 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL28997915 | 0.98 | TP53 (0.57) | TP53OPRM1CA2SPHK1LAP3 | |
| SCHEMBL222613 | 0.93 | TP53 (0.50) | TP53OPRM1CA2SPHK1CA1 | |
| Trifluoroacetic Acid SCHEMBL28897088 | 0.84 | TP53 (0.49) | TP53OPRM1CA2 | |
| SCHEMBL222996 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | TP53 3570/4885OPRM1 1069/4885CA2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.